Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-κB/GLUT1 axis-Reference-Cited by-同舟云学术

Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-κB/GLUT1 axis

Published:2016-11-24 Issue:52 Volume:7 Page:87271-87283
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Jiang Jie¹,Geng Guojun¹,Yu Xiuyi¹,Liu Hongming¹,Gao Jing¹,An Hanxiang²,Cai Chengfu¹,Li Ning¹,Shen Dongyan³,Wu Xiaoqiang³,Zheng Lisheng⁴,Mi Yanjun¹²,Yang Shuyu⁵

Affiliation:

1. Department of Thoracic Surgery, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China

2. Department of Medical Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China

3. Biobank, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China

4. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, People's Republic of China

5. Xiamen Diabetes Institution, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dihydroartemisinin inhibits HNSCC invasion and migration by controlling miR-195-5p expression;Heliyon;2024-06

2. Research Progress of Warburg Effect in Hepatocellular Carcinoma;Frontiers in Bioscience-Landmark;2024-05-09

3. Target prediction and potential application of dihydroartemisinin on hepatocarcinoma treatment;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-05-07

4. Target prediction and potential application of dihydroartemisin on hepatocarcinoma;2024-04-22

5. Nano Strategies for Artemisinin Derivatives to Enhance Reverse Efficiency of Multidrug Resistance in Breast Cancer;Current Pharmaceutical Design;2023-12